Vieira Ferreira Nuno, Andrade Renato, Pinto Freitas Tânia, de Campos Azevedo Clara, Espregueira-Mendes João, Salgado António J, Sevivas Nuno
Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal.
JSES Rev Rep Tech. 2025 Jan 13;5(2):231-242. doi: 10.1016/j.xrrt.2024.12.003. eCollection 2025 May.
Arthroscopic repair is currently the gold standard for the surgical treatment of rotator cuff tears, but the retear rates remain unacceptably high. Mesenchymal stem cells (MSCs) may play a role in the local biology and enhance tendon-to-bone healing during rotator cuff repair. However, the scientific literature is still not well systematized on the effects of injection of MSCs as an augmentation tool for rotator cuff repair. Our goal was to investigate the effect of injections of MSCs to augment rotator cuff repair in patients with rotator cuff tear.
PubMed and EMBASE were searched up to June 2022 for clinical studies that applied MSCs injections to augment rotator cuff repair. Imaging, patient-reported outcomes measures, shoulder range of motion and strength were collected. Quantitative synthesis included within- and between-group mean differences with the within-group percentage of minimal clinically important difference for each study and continuous outcomes, and relative risks (RR) for retears and adverse events. Quantitative synthesis was computed with 95% confidence intervals (CIs).
We included 5 studies comprising a total of 228 individuals with a weighted mean age of 59.3 ± 1.2 years. Three studies used bone marrow MSCs and two studies applied adipose-derived MSCs. Patient-reported outcomes measures, shoulder range of motion, and strength improved significantly in all MSCs groups, with minimal clinically important differences ranging from 120% to 679% of established cut-off. When compared to rotator cuff repair alone, the MSCs groups did not result in improved outcomes. The MSCs group showed significant protective effect at the mid-term (RR = 0.52, 95% CI 0.27-0.98) and long-term (RR = 0.24, 95% CI 0.11-0.53).
There are no differences in clinical and functional outcomes between rotator cuff repair with or without augmentation with MSCs. However, there may be a protective effect against retear at the mid-term and long-term follow-up when augmenting the repair with MSCs. The literature on this topic is still preliminary and the quality and certainty of evidence is limited.
关节镜修复术目前是肩袖撕裂手术治疗的金标准,但再撕裂率仍然高得令人难以接受。间充质干细胞(MSCs)可能在局部生物学中发挥作用,并在肩袖修复过程中促进肌腱与骨的愈合。然而,关于注射MSCs作为肩袖修复增强工具的效果,科学文献仍未得到很好的系统化整理。我们的目标是研究注射MSCs对肩袖撕裂患者肩袖修复的增强效果。
检索截至2022年6月的PubMed和EMBASE数据库,查找应用MSCs注射增强肩袖修复的临床研究。收集影像学、患者报告的结局指标、肩关节活动范围和力量数据。定量综合分析包括组内和组间平均差异,以及每项研究中最小临床重要差异的组内百分比和连续结局指标,以及再撕裂和不良事件的相对风险(RR)。定量综合分析采用95%置信区间(CIs)计算。
我们纳入了5项研究,共228例个体,加权平均年龄为59.3±1.2岁。3项研究使用骨髓MSCs,2项研究应用脂肪来源的MSCs。所有MSCs组患者报告的结局指标、肩关节活动范围和力量均有显著改善,最小临床重要差异为既定临界值的120%至679%。与单纯肩袖修复相比,MSCs组并未带来更好的结局。MSCs组在中期(RR = 0.52,95% CI 0.27 - 0.98)和长期(RR = 0.24,95% CI 0.11 - 0.53)显示出显著的保护作用。
使用或不使用MSCs增强的肩袖修复在临床和功能结局上没有差异。然而,在中期和长期随访中,使用MSCs增强修复可能对再撕裂有保护作用。关于这一主题的文献仍处于初步阶段,证据的质量和确定性有限。